ADQ to invest $75m in Biocon Biologics.

ADQ, a holding company, agreed to invest $75m in Biocon Biologics, a biopharmaceutical company, valuing the company at $4.17bn. “This investment is an endorsement of the value that the Biocon Biologics business has built as a fully integrated pure-play biosimilars company and will enable us to expand our capabilities further. We are committed to pursue our affordable innovation model to generate savings for the healthcare systems worldwide,” Kiran Mazumdar-Shaw, Biocon Executive Chairperson.